Circulating Biomarker Panels in Alzheimer's Disease

Area of Science:

• Neurology
• Biomarker Discovery
• Molecular Diagnostics

Background:

• Early diagnosis of Alzheimer's disease (AD) remains a significant clinical challenge.
• Current diagnostic methods for AD, including cerebrospinal fluid (CSF) analysis and brain imaging (MRI, PET), are often invasive or costly.
• Developing minimally invasive biomarkers for preclinical AD detection is critical for improving patient outcomes.

Purpose of the Study:

• To review current and emerging circulating biomarkers for Alzheimer's disease (AD).
• To focus on novel biomarker signatures, specifically small noncoding RNA (microRNA) profiles, for AD detection.
• To emphasize the need for further clinical validation of these emerging biomarkers.

Main Methods:

• Review of existing literature on AD diagnostic markers.
• Summary of cerebrospinal fluid (CSF) markers.
• Focus on high-throughput approaches like next-generation sequencing (NGS) for profiling circulating biomarkers, including microRNAs.

Main Results:

• Various circulating biomarker candidates, including mRNAs and proteins, have been proposed for AD.
• Small noncoding RNA (microRNA) profiles in blood samples show promise as novel AD biomarkers.
• Current marker panels are in early developmental stages requiring substantial clinical validation.

Conclusions:

• Circulating microRNA profiles represent a promising avenue for minimally invasive AD diagnosis and prognosis.
• Further research and clinical validation are essential to establish the utility of these novel biomarker signatures.
• Advancements in high-throughput technologies are crucial for identifying robust AD biomarker panels.